阿尔凯默斯 ALKS 深 沪
等待开盘 10-20 09:30:00 美东时间
30.26
-0.540
-1.75%
华盛通- 最 高31.175
- 今 开30.68
- 成交量 204.24万股
- 最 低 30.00
- 昨 收 30.80
- 总市值 49.93亿
- 52周最高 36.45
- 市盈率 静 13.95
- 换手率 1.24%
- 52周最低 25.165
- 委 比 33.59%
- 总股本 1.65亿
- 历史最高 79.041
- 量 比 0.93
- 振 幅 3.81%
- 历史最低 10.311
- 每 手 1
- 风险率 2.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
Alkermes upgraded at RBC Capital Markets ahead of key catalyst
Alkermes (NASDAQ:ALKS) shares spiked on Friday after RBC Capital Markets upgraded the Irish biotech to Outperform from Sector Perform, citing a compelling buying opportunity ahead of a key late-stage ...
09-26 23:12
RBC Capital Upgrades Alkermes to Outperform, Raises Price Target to $44
RBC Capital analyst Leonid Timashev upgrades Alkermes (NASDAQ: ALKS) from Sector Perform to Outperform and raises the price target from $42 to $44.
09-26 19:40
Global Psychotic Disorders Market Poised For Significant Growth
The global market for medications addressing psychotic disorders is projected t...
09-16 17:09
Alkermes Partners with Amneal for VIVITROL® Distribution
Alkermes ( ($ALKS) ) just unveiled an announcement. On September 9, 2025, Alker...
09-13 05:21
Alkermes appoints new CFO
Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS), effective September 15, 2025. Reed previously served as CFO of Omega Therapeutics and Aldeyra Therapeutics (ALDX), ...
09-12 21:08
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Diso...
09-11 19:00
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
美股大行评级 | 潜在涨幅37.57%！Mama's Creations获Roth Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Roth Capital：维持Mama's Creations"买入"评级，目标价从10美元升至13美元；高盛：维持Mineralys Therapeutics"买入"评级，目标价从32美元升至52美元
09-10 09:47
HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $46 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Alkermes (NASDAQ:ALKS) with a Neutral and maintains $46 price target.
09-09 18:48
